Isoliquiritigenin is a potent inhibitor of NLRP3 inflammasome activation and diet‐induced adipose tissue inflammation

Isoliquiritigenin, a component of Glycyrrhiza uralensis, is a potent inhibitor of the NLRP3 inflammasome, and suppresses diet‐induced obesity, adipose tissue inflammation, and metabolic disorders. Inflammasome activation initiates the development of many inflammatory diseases, including obesity and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of leukocyte biology 2014-12, Vol.96 (6), p.1087-1100
Hauptverfasser:	Honda, Hiroe, Nagai, Yoshinori, Matsunaga, Takayuki, Okamoto, Naoki, Watanabe, Yasuharu, Tsuneyama, Koichi, Hayashi, Hiroaki, Fujii, Isao, Ikutani, Masashi, Hirai, Yoshikatsu, Muraguchi, Atsushi, Takatsu, Kiyoshi
Format:	Artikel
Sprache:	eng
Schlagworte:	Adipose Tissue, White - drug effects Adipose Tissue, White - pathology AIM2 Animals Anti-Inflammatory Agents - isolation & purification Anti-Inflammatory Agents - pharmacology Anti-Inflammatory Agents - therapeutic use Carrier Proteins - antagonists & inhibitors caspase‐1 Cell Line, Tumor Chalcones - isolation & purification Chalcones - pharmacology Chalcones - therapeutic use diabetes Diet, High-Fat - adverse effects DNA-Binding Proteins - metabolism Glyburide - pharmacology Glyburide - therapeutic use Glycyrrhiza Glycyrrhiza uralensis - chemistry Glycyrrhizic Acid - pharmacology Glycyrrhizic Acid - therapeutic use glycyrrhizin Humans Hypercholesterolemia - drug therapy IL‐1β Inflammasomes - drug effects Inflammation - prevention & control Insulin Resistance Interleukin-1beta - biosynthesis Islet Amyloid Polypeptide - antagonists & inhibitors Islet Amyloid Polypeptide - pharmacology Lipopolysaccharides - pharmacology Male Mice Mice, Inbred C57BL NLR Family, Pyrin Domain-Containing 3 Protein obesity Obesity - drug therapy Obesity - prevention & control Specific Pathogen-Free Organisms
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!